Sandoz is lined up to copy 10 of the blockbuster drugs on this tracker, which earned $71.5B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Sandoz's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Pyzchiva |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Prolia Jubbonti |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Wyost |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Aug 2026 | $2.7B |
| Enbrel Erelzi |
Amgen | Biosimilar | 2029 | FDA-approved; blocked until 2029 | $2.2B |
| Lynparza | AstraZeneca / Merck | Generic | 2027 | Generic filed; in litigation | $3.3B |
| Otezla | Amgen | Generic | 2028 | Barred by court until Feb 2028 | $2.3B |
| Rinvoq | AbbVie | Generic | 2037 | Settled Sep 2025 | $8.3B |
| Keytruda | Merck | Biosimilar | 2028 | In clinical trials | $31.7B |
Company facts: MarketScreener. Each drug page lists sources for these entries. Brand sales show the size of the market, not Sandoz's share of it.